Non‑ pharmacological treatment of heart failure in terms of the new European guidelines for resynchronization therapy

Česká verzia

Authors: P. Heinc; F. Kováčik; J. Přeček; A. Smékal; I. Šimková; M. Táborský
Authors place of work: I. interní klinika – kardiologická FN Olomouc
Published in the journal: Kardiol Rev Int Med 2014, 16(2): 88-94
Category: Cardiology Review

Summary

The new guidelines for cardiac resynchronization therapy state clinical and ECG features for the greatest benefit of resynchronization therapy, crucial evidence for the indication of cardiac resynchronization therapy, and indications for cardiac resynchronization therapy in patients with heart failure and low ejection fraction of the left ventricle in the presence of both sinus rhythm and atrial fibrillation. In addition, the guidelines provide recommendations for "upgrade" of original permanent cardiac pacing or primary implantation for persistent bradycardia patients and, finally, they define clinical factors that should be taken into account when choosing between a biventricular pacemaker and a biventricular defibrillator for primary prevention of sudden death.

Keywords:
resynchronization therapy – heart failure – optimal choice of pacemaker or defibrillator

Zdroje

1. Khan NK, Goode KM, Cleland JG et al. Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. Eur J Heart Fail 2007; 9: 491– 501.

2. Cleland JG, Freemantle N, Erdmann E et al. Long‑term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization‑ Heart Failure (CARE‑ HF) trial. Eur J Heart Fail 2012; 14: 628– 634. doi: 10.1093/ eurjhf/ hfs055.

3. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547– 1552.

4. Hawkins NM, Petrie MC, MacDonald MR et al. Selecting patients for cardiac resynchronisation therapy: electrical or mechanical dyssynchrony? Eur Heart J 2006; 27: 1270– 1281.

5. Thibault B, Harel F, Ducharme A et al. Cardiac resynchronization therapy in patients with heart failure and a QRS Complex < 120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER‑ EARTH) trial. Circulation 2013; 127: 873– 881. doi: 10.1161/ CIRCULATIONAHA.112.001239.

6. Tang AS, Wells GA, Talajic M et al. Cardiac‑ resynchronization therapy for mild‑ to‑ moderate heart failure. N Engl J Med 2010; 363: 2385– 2395. doi: 10.1056/ NEJMoa1009540.

7. Arshad A, Moss AJ, Foster E et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT‑ CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011; 57: 813– 820. doi: 10.1016/ j.jacc.2010.06.061.

8. Barsheshet A, Goldenberg I, Moss AJ et al. Response to preventive cardiac resynchronization therapy in patiens with ischaemic and nonischaemic cardiomyopathy in MADIT‑ CRT. Eur Heart J 2011; 32: 1622– 1630. doi: 10.1093/ eurheartj/ ehq407.

9. Beshai JF, Grimm RA, Nagueh SF et al. Cardiac‑ resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357: 2461– 2471.

10. Hayes DL, Boehmer JP, Day JD et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8: 1469– 1475. doi: 10.1016/ j.hrthm.2011.04.015.

11. Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac resynchronization therapy pacing: insights from 32 844 patients. Circ Arrhythm Electrophysiol 2012; 5: 884– 888. doi: 10.1161/ CIRCEP.112.973776.

12. Saxon LA, Olshansky B, Volosin K et al. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol 2009; 20: 764– 768. doi: 10.1111/ j.1540– 8167.2009.01444.x.

13. Thebault C, Donal E, Meunier C et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J 2012; 33: 2662– 2671. doi: 10.1093/ eurheartj/ ehr505.

14. Khan FZ, Virdee MS, Palmer CR et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012; 59: 1509– 1518. doi: 10.1016/ j.jacc.2011.12.030.

15. Ellenbogen KA, Gold MR, Meyer TE et al. Primary results from the SmartDelay determined AV optimization: a comparison with other AV delay methods used in cardiac resynchronization therapy (SMART‑ AV) trial: a randomized trial comparing empirical, echocardiography‑ guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010; 122: 2660– 2668. doi: 10.1161/ CIRCULATIONAHA.110.992552.

16. Liang Y, Pan W, Su Y et al. Meta‑analysis of randomized controlled trials comparing isolated left ventricular and biventricular pacing in patients with chronic heart failure. Am J Cardiol 2011; 108: 1160– 1165. doi: 10.1016/ j.amjcard.2011.06.018.

17. Ganesan AN, Brooks AG, Roberts‑ Thomson KCet al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012; 59: 719– 726. doi: 10.1016/ j.jacc.2011.10.891.

18. Chatterjee NA, Upadhyay GA, Ellenbogen KA et al. Atrioventricular nodal ablation in atrial fibrillation: a meta‑analysis and systematic review. Circ Arrhythm Electrophysiol 2012; 5: 68– 76. doi: 10.1161/ CIRCEP.111.967810.

19. Chen L, Hodge D, Jahangir A et al. Preserved left ventricular ejection fraction following atrioventricular junction ablation and pacing for atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19: 19– 27.

20. Khan MN, Jais P, Cummings J et al. Pulmonary‑ vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778– 1785. doi: 10.1056/ NEJMoa0708234.

21. Dickstein K, Bogale N, Priori S et al. The European cardiac resynchronization therapy survey. Eur Heart J 2009; 30: 2450– 2460. doi: 10.1093/ eurheartj/ ehp359.

22. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double‑blind, randomized crossover study. Europace 2006; 8: 51– 55.

23. van Geldorp IE, Vernooy K, Delhaas T et al. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace 2010; 12: 223– 229. doi: 10.1093/ europace/ eup378.

24. Poole JE, Gleva MJ, Mela T et al. Complication rates associated with pacemaker or implantable cardioverter‑ defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122: 1553– 1561. doi: 10.1161/ CIRCULATIONAHA.110.976076.

25. Albertsen AE, Nielsen JC, Poulsen SH et al. Biventricular pacing preserves left ventricular performance in patients with high‑grade atrio‑ ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patients. Europace 2008; 10: 314– 320. doi: 10.1093/ europace/ eun023.

26. Stockburger M, Gomez‑ Doblas JJ, Lamas G et al. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multi‑centre international randomized trial (PREVENT‑ HF). Eur J Heart Fail 2011; 13: 633– 641. doi: 10.1093/ eurjhf/ hfr041.

27. Laurenzi F, Achilli A, Avella A et al. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol 2007; 30: 1096– 1104.

28. Vatankulu MA, Goktekin O, Kaya MG et al. Effect of long‑term resynchronization therapy on left ventricular remodelling in pacemaker patients upgraded to biventricular devices. Am J Cardiol 2009; 103: 1280– 1284. doi: 10.1016/ j.amjcard.2009.01.023.

29. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539– 1549.

30. Kleemann T, Becker T, Doenges K et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter‑ defibrillators over a period of > 10 years. Circulation 2007; 115: 2474– 2480.